Product Description
Balicatib, an inhibitor of the osteoclastic enzyme cathepsin K, was tested in ovariectomized monkeys, a model for osteoporosis. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/21308366/)
Mechanisms of Action: CTSK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Osteoporosis|Bone Diseases, Metabolic|Osteoarthritis|Osteophyte|Osteoarthritis, Knee
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Depressive Disorder |
2018-06-01 |
|
| 2007-002243-25 | P2 |
Completed |
Osteoporosis |
2008-09-25 |
|
| 2203E1 | P2 |
Terminated |
Osteoporosis |
2007-09-17 |
|
| 2201 | P2 |
Completed |
Osteophyte|Osteoarthritis |
2006-07-27 |